The Pfizer booster trial is pretty spectacular.
— Devan Sinha (@DevanSinha) October 21, 2021
10k previously 2x dosed (median 11 months from dose 2).
Randomised 1:1 placebo and 30ug.
95.6% relative risk reduction in symptomatic infection in intervention arm vs control (2dose only).
5 v 109 events 7+ days from boost.